Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2011

01-03-2011 | Original Paper

Osteolytic lesions marker in multiple myeloma

Authors: Irena Djunic, Ivo Elezovic, Milica Marinkovic, Nada Suvajdzic-Vukovic, Dragica Tomin, Gradimir Jankovic, Jelena Bila, Darko Antic, Ana Vidovic, Borka Neskovic, Dragica Nikolic-Vukosavljevic

Published in: Medical Oncology | Issue 1/2011

Login to get access

Abstract

The degradation product of collagen type I carboxy terminal telopeptide (ICTP) represents a new biochemical parameter that reflects the changes in the resorption properties of skeletal system. Affection of the skeleton is one of the most important characteristics of multiple myeloma (MM). We estimated significance of ICTP as osteolysis predictor and overall survival in comparison with standard prognostic parameters β2-microglobulin and C-reactive protein (CRP), in patients with MM. With our results, we have shown significant difference in serum level of ICTP (P = 0.009) between patients with and without osteolysis on conventional radiography. It was proved that ICTP is the most significant predictor of osteolysis (P = 0.09), while CRP is the most significant risk factor for overall survival (P < 0.01). Being highly significant predictor of osteolysis, ICTP can be used for identification of patients with MM who had increased risk for developing osteolytic lesions.
Literature
1.
Kyle RA. Multiple myeloma, review of 869 cases. Mayo Clin Proc. 1975;50:29–40.PubMed
2.
Abilgard N, Brixen K, Eriksen EF, Kristensen JE, Nilsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica. 2004;89:567–77.
3.
Jakob C, Zavirski I, Heider U, et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res. 2003;9:3047–51.PubMed
4.
Dimopoulos MA, Moulopoulos LA, Datseris I, et al. Imaging of myeloma bone disease-implications for staging, prognosis and follow-up. Acta Oncol. 2000;39:823–7.PubMedCrossRef
5.
Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol. 1999;104:723–9.PubMedCrossRef
6.
Moulopoulos LA, Dimopoulos MA. Magnetic resonance imging of bone marrow in hematologic malignancis. Blood. 1997;90:2127–47.PubMed
7.
Abilgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol. 2000;64:124–9.
8.
Abilgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: eleveted pretreatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haem. 2003;120:235–42.CrossRef
9.
Batallie R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event of pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62–6.CrossRef
10.
Batallie R, Chappard D, Marcelli C, et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol. 1990;76:484–7.CrossRef
11.
Dizdar O, Barista I, Umut K, et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Haemat. 2007;82:185–91.CrossRef
12.
Abilgaard N, Bentzen S, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haem. 1997;96:103–10.CrossRef
13.
Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem. 1997;30:573–93.PubMedCrossRef
14.
Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (Ntx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol. 2002;69:37–42.PubMedCrossRef
15.
Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin rations. Eur J Haematol. 1999;62(5):300–6.PubMedCrossRef
16.
Risteli J, Elomas I, Nieml S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone degradation. Clin Chem. 1993;39(4):635–40.PubMed
17.
Elmoaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992;66(2):337–41.CrossRef
18.
Fonseca R, Trendle MC, Leong T, et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol. 2000;109:24–9.PubMedCrossRef
19.
Batallie R, Boccadoro M, Klein B, Durie BG, Pileri A. C-reactive protein and β2-microglobulin produce a simple and powerful myeloma staging sistem. Blood. 1992;80:733–7.
Metadata
Title
Osteolytic lesions marker in multiple myeloma
Authors
Irena Djunic
Ivo Elezovic
Milica Marinkovic
Nada Suvajdzic-Vukovic
Dragica Tomin
Gradimir Jankovic
Jelena Bila
Darko Antic
Ana Vidovic
Borka Neskovic
Dragica Nikolic-Vukosavljevic
Publication date
01-03-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9432-4

Other articles of this Issue 1/2011

Medical Oncology 1/2011 Go to the issue

Original Paper

Recurrent differentiation syndrome or septic shock? Unresolved dilemma in a patient with acute promyelocytic leukemia

Original Paper

A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib

Original Paper

Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study

Original Paper

Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells

Original Paper

Nitrative and oxidative DNA damage as potential survival biomarkers for nasopharyngeal carcinoma

Original Paper

CYP2E1 Rsa I/Pst I polymorphism and esophageal cancer risk: a meta-analysis based on 1,088 cases and 2,238 controls

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits